Loading
Total declarations
Company
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Latest filing published 31 Jan 2018 for REPROS THERAPEUTICS INC., €13k.
Insider track record
Disclosed buys
2
Disclosed sells
0
Signal history
Closed purchases
Market purchases
2
Not enough history yet: 0 closed purchases, at least 2 are needed.
Purchases by company
Daniel F. Cain: trading record in brief
All filings by Daniel F. Cain on record concern Repros Therapeutics Inc. We count 6 filings; the first trade dates from 27 July 2006 and the latest from 31 January 2018.
Purchases make up the whole of the open-market record (2 purchases, €19k). Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 1 share grant and 1 option exercise.
The newest entry dates from 31 January 2018: a transaction of €13k, in Repros Therapeutics Inc. The most recent open-market purchase was published on 14 November 2013, 4,726 days ago. The median gap between a trade and its publication by SEC (Form 4) is 1 day. US insiders must file a Form 4 within two business days of a trade. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Daniel F. Cain
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations6 total
23,221 shares@ US$0.6745.5% of flowCommon StockSEC:0001144204-18-004779:0
27,779 shares@ US$0.6754.5% of flowCommon StockSEC:0001144204-18-004779:1
40,000 sharesCommon StockSEC:0001144204-17-009369:0
10,000 shares@ US$9.60Common StockSEC:0001144204-14-001664:0
500 shares@ US$14.97Common StockSEC:0001274244-13-000001:0
Canonical exit: 10 Feb 2014 (T+90)
2,000 shares@ US$8.34Common StockSEC:0001181431-06-044078:0
Canonical exit: 25 Oct 2006 (T+90)
6 of 6 declarations
